COVID-19 Coagulopathy and Inflammation: The Knowns and Unknowns

Anesth Analg. 2020 Nov;131(5):1323. doi: 10.1213/ANE.0000000000005215.

Authors

Jonathan P Wanderer¹, Naveen Nathan²

Affiliations

¹ Vanderbilt University School of Medicine (jon.wanderer@vanderbilt.edu).
² Northwestern University Feinberg School of Medicine (n-nathan@northwestern.edu).

PMID: 33079849
DOI: 10.1213/ANE.0000000000005215

No abstract available

MeSH terms

Anticoagulants / therapeutic use
Betacoronavirus / pathogenicity*
Biomarkers / blood
Blood Coagulation* / drug effects
COVID-19
Coronavirus Infections / blood*
Coronavirus Infections / mortality
Coronavirus Infections / therapy
Coronavirus Infections / virology
Fibrin Fibrinogen Degradation Products / analysis
Hospital Mortality
Host-Pathogen Interactions
Humans
Inflammation / blood*
Inflammation / mortality
Inflammation / therapy
Inflammation / virology
Inflammation Mediators / blood
Pandemics
Pneumonia, Viral / blood*
Pneumonia, Viral / mortality
Pneumonia, Viral / therapy
Pneumonia, Viral / virology
Prognosis
Risk Factors
SARS-CoV-2
Venous Thromboembolism / blood*
Venous Thromboembolism / mortality
Venous Thromboembolism / therapy
Venous Thromboembolism / virology

Substances

Anticoagulants
Biomarkers
Fibrin Fibrinogen Degradation Products
Inflammation Mediators
fibrin fragment D